BNTX Q2 2025 Earnings
Reported Aug 4, 2025 at 8:01 AM ET · SEC Source
Q2 25 EPS
$-1.85
MISS 31.65%
Est. $-1.41
Q2 25 Revenue
$301.6M
BEAT +14.39%
Est. $263.7M
vs S&P Since Q2 25
-27.3%
TRAILING MARKET
BNTX -12.5% vs S&P +14.8%
Market Reaction
Did BNTX Beat Earnings? Q2 2025 Results
BioNTech delivered a mixed second quarter for 2025, posting revenues that more than doubled year over year while its bottom line fell short of expectations. Revenue came in at $301.62 million, a 102.6% increase from a year earlier and well ahead of t… Read more BioNTech delivered a mixed second quarter for 2025, posting revenues that more than doubled year over year while its bottom line fell short of expectations. Revenue came in at $301.62 million, a 102.6% increase from a year earlier and well ahead of the $263.68 million consensus estimate, driven by a 113% surge in COVID-19 vaccine sales to $177.29 million on higher dose volumes. However, the earnings picture was less encouraging, with BioNTech reporting a loss per share of $1.85, missing the $1.41 consensus estimate by 31.65%, as the company continued to absorb heavy R&D investment and $50.42 million in pipeline prioritization charges tied to site capacity adjustments and workforce reductions. The headline strategic development was a co-development agreement with Bristol Myers Squibb for cancer immunotherapy candidate BNT327, which could deliver up to $11.10 billion in total payments. Looking ahead, BioNTech is preparing for the 2025/2026 COVID-19 vaccination season and expects first data from its adjuvant colorectal cancer trial by early 2026, even as analysts project a meaningful revenue decline for the full year.
Key Takeaways
- • COVID-19 vaccine revenue increase of 113% YoY driven by higher volume of doses sold
- • Other revenue increase from German government pandemic preparedness contract and one-time effect from Pfizer BNT167 opt-out
- • R&D expense reduction of 13% from reprioritization of clinical trials toward focus programs
- • G&A expense reduction of 31% from lower external services
- • Absence of €239.1M contractual dispute charges from prior year quarter
BNTX YoY Financials
Q2 2025 vs Q2 2024, source: SEC Filings
BNTX Revenue by Segment
Business unit performance breakdown
BNTX Earnings Trends
BNTX vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
BNTX EPS Trend
Earnings per share: estimate vs actual
BNTX Revenue Trend
Quarterly revenue: estimate vs actual
BNTX Quarterly Results
4 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 | $-2.14 | — | — | — | — |
| Q4 25 MISS FY | $-0.25 | $-1.25 | -405.66% | $907.4M | +24.34% |
| FY Full Year | $-3.44 | $-4.70 | -36.62% | $2.87B | +6.60% |
| Q3 25 MISS | $0.10 | $-0.12 | -220.36% | — | — |
| Q2 25 MISS | $-1.41 | $-1.85 | -31.65% | $301.6M | +14.39% |